Company news

Pliant Therapeutics, Inc. news in 2026

Pliant Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Pliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer

October 29, 2026

Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA)

October 20, 2026

Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026

October 19, 2026

Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer

September 30, 2026

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors

August 18, 2026

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

August 11, 2026

Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors

July 13, 2026

Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

May 21, 2026

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

May 11, 2026

Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

May 6, 2026

Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors

April 30, 2026

Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting

April 18, 2026

Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting

March 17, 2026

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results

March 11, 2026

Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference

February 22, 2026

Enhanced Genomics Appoints Dr Katerina Leftheris to Its Board of Directors

January 9, 2026

Decks in 2026